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Background: Patients undergoing alcohol withdrawal in the intensive care unit (ICU) often require escalating
doses of benzodiazepines and not uncommonly require intubation and mechanical ventilation for airway
protection. This may lead to complications and prolonged ICU stays. Experimental studies and single case reports
suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol
withdrawal. We report a retrospective analysis of 20 ICU patients treated with dexmedetomidine for
benzodiazepine-refractory alcohol withdrawal.
Methods: Records from a 23-bed mixed medical-surgical ICU were abstracted from November 2008 to November
2010 for patients who received dexmedetomidine for alcohol withdrawal. The main analysis compared alcohol
withdrawal severity scores and medication doses for 24 h before dexmedetomidine therapy with values during the
first 24 h of dexmedetomidine therapy.
Results: There was a 61.5% reduction in benzodiazepine dosing after initiation of dexmedetomidine (n = 17;
p< 0.001) and a 21.1% reduction in alcohol withdrawal severity score (n = 11; p = .015). Patients experienced less
tachycardia and systolic hypertension following dexmedetomidine initiation. One patient out of 20 required
intubation. A serious adverse effect occurred in one patient, in whom dexmedetomidine was discontinued for two
9-second asystolic pauses noted on telemetry.
Conclusions: This observational study suggests that dexmedetomidine therapy for severe alcohol withdrawal is
associated with substantially reduced benzodiazepine dosing, a decrease in alcohol withdrawal scoring and
blunted hyperadrenergic cardiovascular response to ethanol abstinence. In this series, there was a low rate of
mechanical ventilation associated with the above strategy. One of 20 patients suffered two 9-second asystolic
pauses, which did not recur after dexmedetomidine discontinuation. Prospective trials are warranted to compare
adjunct treatment with dexmedetomidine versus standard benzodiazepine therapy.
Keywords: Alcohol withdrawal delirium, Alcohol withdrawal syndrome, Dexmedetomidine, Intensive care, Critical
care, BenzodiazepinesBackground
The medical consequences of excessive alcohol use are all
too familiar to clinicians. Alcohol abuse and dependence
have a combined prevalence of 7.4–9.7% in the United
States [1]. This increases to 10–33% in intensive care unit
(ICU) patients; 18% of these patients develop acute with-
drawal symptoms during their hospitalization [2]. Alcohol
withdrawal syndrome (AWS) is an abstinence syndrome
characterized by autonomic hyperactivity, hallucinations,* Correspondence: rayn0011@umn.edu
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in any medium, provided the original work is pand seizures, termed alcohol withdrawal delirium or delir-
ium tremens when accompanied by a persistent altered
sensorium and severe hyperadrenergic state. This severe
form of withdrawal develops in approximately 5% of
patients who abruptly cease ethanol ingestion, often dur-
ing an acute medical illness, and generally begins within
48–96 h after cessation of alcohol intake [3-5].
Chronic ethanol ingestion leads to changes in the expres-
sion patterns of inhibitory γ-aminobutyric acid (GABA)
receptors within the central nervous system (CNS) and in-
hibition of the excitatory glutamate system. With cessation
of alcohol intake, disrupted GABA signaling and reboundn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Rayner et al. Annals of Intensive Care 2012, 2:12 Page 2 of 6
http://www.annalsofintensivecare.com/content/2/1/12increase in glutamate signaling produce CNS hyperexcita-
tion leading to the clinical manifestations of alcohol with-
drawal [6-8]. Increases in noradrenergic and dopaminergic
signaling may play a role in autonomic instability and alco-
holic hallucinations, respectively [3,9,10]. Benzodiazepines,
which act through GABA receptors, are logical interven-
tions for abstinence-associated CNS excitation, and reduce
symptom duration, delirium, incidence of seizure and, in
trials comparing benzodiazepines with neuroleptics, mor-
tality [4,11,12]. In severe AWS, however, benzodiazepine
monotherapy may be less effective. Patients with significant
tolerance to alcohol exhibit cross-tolerance to the GABA-
mediated effects of benzodiazepines, and the requirement
for high doses of benzodiazepines can lead to oversedation,
respiratory insufficiency, and worsening of delirium
[4,13,14]. Large doses of benzodiazepines increase the risk
of aspiration and intubation, increasing complication rates,
length of stay, and hospital costs [14].
Anticonvulsants may have efficacy similar to benzodia-
zepines in mild-moderate alcohol withdrawal, but limited
data suggest lower efficacy in AWS [15,16]. β-adrenore-
ceptor antagonists and the α2 adrenoreceptor agonist clo-
nidine are used to reduce autonomic symptoms but have
not been well studied in critical care cases, and certain
agents (e.g., propranolol) may worsen delirium [4,15,17].
Propofol, which acts through both GABAergic and gluta-
matergic pathways in the CNS, is effective in the manage-
ment of benzodiazepine-refractory AWS, but the majority
of patients who receive propofol require intubation during
treatment [18,19]. Propofol therapy also causes hypertri-
glyceridemia, hypotension, and is associated with the pro-
pofol infusion syndrome [18].
The α2 agonist, dexmedetomidine, is indicated for sed-
ation of mechanically ventilated patients in the ICU and
procedural sedation in nonintubated patients [20,21]. It
has shown efficacy in murine models and single human
case reports of alcohol withdrawal [22-25]. There also
are reports of dexmedetomidine for nonethanol or poly-
agent withdrawal syndromes [26,27]. We report our
experience using dexmedetomidine for benzodiazepine-
refractory AWS in a single ICU.
Methods
Treatment information
This study was approved by the University of Minnesota
Human Subjects Protection Program (approval code num-
ber 1101 M94834) and a waiver of informed consent for
data abstraction was granted for patients admitted to the
open 23-bed medical-surgical-neuroscience ICU at the Fair-
view-Southdale Hospital. Treatment of patients with alco-
hol withdrawal symptoms involves standardized physician
orders, including vitamin, electrolyte, and intravenous fluid
replacement therapy. Additionally, a nursing-administered
alcohol withdrawal severity assessment protocol is utilized,with ten parameters consisting of vital signs and physical
and behavioral findings, which are assessed and assigned a
point value from 1–3 [28]. Ranges of total points are linked
to dose ranges of intravenous or oral lorazepam that nurs-
ing personnel can administer, from none for a total score
below 4, to a maximum range of 2–4 mg for a score above
10. Frequency of withdrawal scoring depends on prior score
and route of lorazepam administration, with a minimum of
every 4 h and a maximum of every 10 min for intravenous
lorazepam therapy or every hour for oral lorazepam ther-
apy. Standing orders may include 2 mg of intravenous halo-
peridol per hour for severe agitation or hallucinations. This
protocol may be initiated on the general wards, with trans-
fer to the ICU based on clinical judgment and need for
monitoring during high-dose benzodiazepine therapy. Dex-
medetomidine is not administered on the general wards.
Any decision to initiate dexmedetomidine is made by
board-certified intensivists, and there is no specific protocol
regarding dexmedetomidine therapy for alcohol withdrawal.
Sample selection
The electronic medical record was reviewed for ICU
patients from November 2008 to November 2010 who
received ICD-9 codes consistent with alcohol withdrawal
during hospitalization. These medical records were exam-
ined for patients who received dexmedetomidine during
their ICU stay, and clinician documentation was examined
to ensure that dexmedetomidine was received solely for the
management of alcohol withdrawal symptoms. Patients
were excluded who had severe comorbid disease, including
several with CNS trauma or cerebrovascular accidents, one
with end-stage metastatic carcinoma, and one patient with
severe sepsis. To reduce selection bias, all consecutive
patients who met study criteria were included.
Data collection
Data from 24 h before dexmedetomidine initiation to 24 h
after were abstracted into a predefined Excel template. We
abstracted hourly dose of dexmedetomidine, benzodiaze-
pines, and haloperidol, alcohol withdrawal score, use of
dexmedetomidine bolus, administration of β-blocking
medications, intubation requirements, length of ICU stay,
hourly systolic blood pressure and heart rate, hours spent
with heart rate<60 or >100 beats per minute, and hours
with systolic blood pressure<90 or>140 mm Hg. Clin-
ician-documented adverse effects of dexmedetomidine
were recorded. The few instances of diazepam or midazo-
lam administration were converted to lorazepam dosing
using factors of 0.2 and 0.5 respectively [29].
Statistical analysis
We compared group means in the 24 h before dexmede-
tomidine administration with means for the first 24 h of
dexmedetomidine therapy. We present the difference
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interval for this difference. Normality was checked for
all variables under study using D’Agostino-Pearson test-
ing, and paired two-tailed t tests were used to compare
group means with p< 0.05 defined as significant. Be-
cause we depended on clinical documentation done dur-
ing routine care, there were missing data, especially in
alcohol withdrawal severity scoring where analysis was
limited to the 11 patients with complete scoring data.Results
There were 19 male subjects and 1 female subject, with a
mean age of 44.9 years (95% confidence interval (CI), 40.9-
48.9). One patient required intubation and all survived to
discharge. Mean length of stay in the ICU was 98.5 h (95%
CI, 54.0-143.0). For the 19 nonintubated patients, mean
length of dexmedetomidine therapy was 49.1 h (95% CI,
36.8-61.4) and mean dexmedetomidine dose was 0.53 μg/
kg/h (95% CI, 0.44-0.62). Five patients received bolus ther-
apy on initiation of dexmedetomidine. Three patients had
less than 24 h of information available before dexmedeto-
midine initiation. One of these patients had 6 hours of
baseline information available and was used in calculations
of mean vitals but not calculations of time with vitals out-
side of defined ranges. The other two had almost no base-
line data and were excluded from analysis. One patient was
intubated 13 h after dexmedetomidine initiation and was
not included in analyses of medication dosing or vitals, be-
cause, once intubated, he received additional sedative and
analgesic agents based on a separate nursing-driven order
set for ventilated patients. Finally, all other patients were
on dexmedetomidine for at least 24 h, except for one who
was on dexmedetomidine for a total of 14 h. This patient’s
data were extrapolated to 24 h for statistical analysis. The
sample sizes for separate analyses are reported below.
D’Agostino-Pearson testing demonstrated normality for all
variables under study (p> 0.1).Benzodiazepine and haloperidol dosing
Seventeen patients were available for analysis of benzodi-
azepine dosing. A statistically significant mean 32.4 mg
(61.5%) per 24 h decrease in benzodiazepine dose
(p< 0.001; 95% CI, 16.7-48.1) was administered in the 24 h
period following dexmedetomidine initiation (Table 1).
Whereas patients often received some oral benzodiazepine
therapy upon initial presentation, most medication was pro-
vided intravenously. Figure 1 shows that the escalating dose
of benzodiazepines rapidly decreases after initiation of dex-
medetomidine. Mean haloperidol dosing in the same 17
patients decreased by 5.6 mg (46.7%) per 24 h (p=0.052;
95% CI, −0.03–11.23) following initiation of dexmedetomi-
dine (Table 1).Alcohol withdrawal scoring
Complete data for 11 patients were analyzed for alcohol
withdrawal scoring. There was a mean decrease of 1.9
points (21.1%) on the alcohol withdrawal severity scale
(p< 0.015; 95% CI .44-3.36) in the 24 h period following
dexmedetomidine initiation (Table 1). Due to the sample
size for this variable, non-parametric analysis with two-
tailed Wilcoxon matched pairs testing was also done and
significant (p< 0.03). Figure 1 shows a rapid decrease in
the score within the first 4 h after initiation of dexmede-
tomidine with a slower decline over the next 20 h.
Heart rate and administration of β-blocking medications
A sample size of 17 patients was used for mean heart rate
analysis. There was a statistically significant decrease in heart
rate by 23.4 beats per minute (22.8%) in the 24 h following
dexmedetomidine initiation (p< 0.001; 95% CI, 18.4-28.4).
In a sample size of 16, there was a statistically significant de-
crease of 10.9 h (82%) spent with heart rate >100 beats per
minute (p< 0.001; 95% CI, 7.4-14.4) in the 24 h after dex-
medetomidine initiation (Table 1). Of the 20 study patients,
4 were continued on their outpatient β-blockers while in the
ICU. Additionally, during their ICU stays two patients
received oral metoprolol once, one patient received oral
metoprolol twice, one patient was given IV labetalol twice,
and one patient received both oral metoprolol and IV labe-
talol occasionally.
Blood pressure
A sample size of 17 patients was used for analysis of mean
systolic blood pressure. There was a statistically significant
decrease in systolic blood pressure of 13.5 mm Hg (9.6%)
following dexmedetomidine initiation (p= 0.002; 95% CI,
3.8-15.4%). In a sample size of 16, there was a statistically
significant decrease of 4.7 h (42.3%) in time with systolic
blood pressure above 140 mm Hg (p= 0.02; 95% CI, 0.8-
8.6) in the 24 h following dexmedetomidine initiation
(Table 1). Figure 2 shows that previously elevated heart
rate and blood pressure decrease sharply during the first 2
hours after initiation of dexmedetomidine.
Adverse outcomes
One patient out of 20 was intubated for respiratory failure.
Significant adverse effects related to dexmedetomidine
therapy were suspected in only one patient, in whom dex-
medetomidine was discontinued due to two 9-second
asystolic pauses. These were noted on telemetry and did
not require specific treatment. No further abnormalities in
heart rate/rhythm were noted following discontinuation of
dexmedetomidine. Finally, there were nonstatistically sig-
nificant increases in bradycardia (<60 beats per minute)
and systolic hypotension (<90 mm Hg) with p values of
0.055 and 0.079 respectively. These patients did not suffer













p value 95% Confidence
interval for decrease
seen after dex initiation
Average Alcohol Withdrawal Scoring 11 9.0 7.1 1.9 (21.1%) 0.015 0.44–3.36(4.9%–37.3%)
Average Benzodiazepines Received (mg) 17 52.7 20.3 32.4 (61.5%) <0.001 16.7–48.1(31.7%–91.3%)
Average Haloperidol Received (mg) 17 12.0 6.4 5.6 (46.7%) 0.052 0.03–11.23(−0.36–93.6%)
Average HR 17 102.8 79.3 23.4 (22.8%) <0.001 18.4–28.4(17.9%–27.6%)
Average SBP 17 140.2 126.7 13.5 (9.6%) 0.002 5.32–21.68(3.8%–15.4%)
Hours With HR> 100 16 13.3 2.3 10.9 (82.0%) <0.001 7.4–14.4(55.6–108.3%)
Hours With SBP >140 16 11.0 6.3 4.7 (42.3%) 0.02 0.8–8.6(3.8–15.4%)
Hours With HR <60 16 0.0 2.0 −2.0 0.055 4.05–0.05
Hours With SBP <90 16 0.0 0.9 −0.9 0.079 1.89–0.09
For dosing, total dose per 24 h period for each patient was averaged. For average vitals, mean values per 24 h period for each patient were averaged. For vitals
outside normal range, total time outside normal range was calculated for each patient per 24 h period, and averaged. A sample size of 16 (instead of 17) was
used for analyses of time spent with vitals outside normal, due to one patient having only six hours of available data. P values obtained from two-tailed paired
t-tests. 95% confidence interval was calculated using t distribution for a paired sample and n-1 degrees of freedom. Dex = dexmedetomidine; SBP = systolic blood
pressure; HR = heart rate.
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sure below 80.
Discussion
In this study, dexmedetomidine use in patients with se-
vere alcohol withdrawal symptoms led to rapid and sta-
tistically significant reductions in benzodiazepine dosing,
alcohol withdrawal score, tachycardia, and systolic
hypertension. Most effects occurred within 4 h of dex-
medetomidine initiation (with bolus dose at initiation
used in only 5 patients) and were sustained over 24 h.
Dexmedetomidine rates less than 0.7 μg/kg/h were gen-
erally sufficient. Intubation was required only in one pa-
tient who, importantly, had received the highest amount
of lorazepam before dexmedetomidine initiation of any
patient. The only adverse effect that required discontinu-
ation of therapy was occurrence of two 9-second asystolic
pauses in one patient, which resolved with discontinuation
of dexmedetomidine. This patient received an initial bolus
of dexmedetomidine of 1 μg/kg and a high average infu-
sion rate of 0.75 μg/kg/h, both of which are associated in
the literature with symptomatic bradycardia [21]. There
were nonsignificant increases in mild hypotension and
bradycardia (systolic blood pressure 80–90 and heart rate
50–60, respectively) following dexmedetomidine initiation.
Our study adds to growing literature on the potential
use of dexmedetomidine for AWS. Studies performed in
mice found that dexmedetomidine reduced rigidity,
tremor, and irritability during ethanol withdrawal, while
exhibiting neuroprotective effects and potential antiepi-
leptic activity [22,23,30]. Two case reports support the
use of dexmedetomidine in benzodiazepine-refractory
AWS [24,25]. Dexmedetomidine also was applied suc-
cessfully in patients undergoing sedative/analgesic orpolysubstance withdrawal in two case series consisting
of two and three patients, respectively [26,27].
Dexmedetomidine has the ability to produce arousable
sedation without respiratory depression [21,31,32].
Through actions on α2 receptors dexmedetomidine leads
to sedation, analgesia, inhibition of the sympathetic ner-
vous system, and increased cardiac vagal tone [33,34].
These characteristics make dexmedetomidine attractive
for treatment of the hyperadrenergic state seen during
alcohol withdrawal. Dexmedetomidine has advantages
over midazolam and lorazepam in providing sedation
with minimal delirium and over haloperidol in managing
intubated delirious patients [35-37]. Additional advan-
tages of dexmedetomidine are its rapid onset and rela-
tively short half-life, as well as its favorable side effect
profile [38]. Pharmacologically, dexmedetomidine has
advantages over the α2 agonist clonidine given its greater
titratability (half-life of 2.3 h versus 6–10 h for clonidine)
and its eightfold greater selectivity for the α2 receptor,
which is thought to be involved in centrally mediated
anxiolysis and sedation [34,39]. The use of dexmedeto-
midine does have risks of hypotension and bradycardia,
although a recent meta-analysis found no difference in
rates of hypotension requiring intervention between
dexmedetomidine and other sedatives, and found a risk
of significant bradycardia only when a loading dose or
rates over 0.7 μg/kg/h were employed [20,21]. Continu-
ous cardiac monitoring is advised and care should be
taken in patients with advanced heart block, severe ven-
tricular dysfunction, hypovolemia, or when receiving
other vasodilators or negative chronotropic agents. Dose
reduction may be necessary in patients with hepatic dys-
function. For further information regarding use, dosing,
indications, and adverse effects, we refer the reader to a
Figure 1 Average alcohol withdrawal scoring and average
benzodiazepine dose (mg) versus initiation of
dexmedetomidine therapy. Alcohol withdrawal scores were
averaged each hour for all patients with complete data available
(n = 11) as was average hourly benzodiazepine dose in mg (n = 17).
Measurements were recorded from 24 h prior to dexmedetomidine
therapy through the first 24 h on dexmedetomidine. Negative
numbers represent data prior to the initiation of the study drug and
the time point 0 represents the initiation of dexmedetomidine. Error
bars reflect the standard error around each mean value.
Figure 2 Hourly systolic blood pressure and heart rate versus
initiation of dexmedetomidine therapy. Systolic blood pressure
and heart rate values were averaged each hour for all 16 patients
with data available. Measurements were recorded from 24 h prior to
dexmedetomidine therapy through the first 24 h on
dexmedetomidine. Negative numbers represent data prior to the
initiation of the study drug and the time point 0 represents the
initiation of dexmedetomidine. Error bars reflect the standard error
around each mean value.
Rayner et al. Annals of Intensive Care 2012, 2:12 Page 5 of 6
http://www.annalsofintensivecare.com/content/2/1/12recent review of this medication as well as the manufac-
turer’s website [39,40].
Our study is limited by its retrospective nature and
lack of a control group. Additionally, our ICU does not
have a protocol specifying when dexmedetomidine
should be added to benzodiazepine therapy; therefore,
dexmedetomidine was likely started at different points in
the alcohol withdrawal process as clinicians’ thresholds
for determining that benzodiazepine therapy had “failed”
may differ. One limitation of dexmedetomidine therapy
itself is that it may not have the ability to prevent alco-
hol withdrawal seizures. Whereas laboratory/rodent
models provide some support for α2 agonists as anticon-
vulsants, an older study comparing clonidine with trad-
itional therapy for alcohol withdrawal seizures was not
promising, and dexmedetomidine cannot currently be
recommended as monotherapy for AWS [22,41].Conclusions
The ability to provide sedation and reduce autonomic
hyperactivity with potentially less respiratory distress
and delirium than seen with benzodiazepine therapy
makes dexmedetomidine an attractive adjunct medica-
tion for the treatment of severe alcohol withdrawal. It is
especially appealing when symptoms are refractory to
high doses of benzodiazepines, because it acts through aGABA-independent pathway. In this study, adjunct ther-
apy with dexmedetomidine in severe alcohol withdrawal
patients poorly controlled on, or experiencing significant
adverse effects with, traditional therapy led to reductions
in benzodiazepine dosing, a decrease in alcohol with-
drawal scoring, and decreases in heart rate and blood
pressure. The uncontrolled, retrospective nature of our
study precludes definite conclusions about the efficacy
or safety of dexmedetomidine for severe alcohol with-
drawal. At this time, a prospective, controlled study is
indicated to help determine whether dexmedetomidine
as adjunct therapy for severe alcohol withdrawal truly
leads to clinically meaningful outcomes, such as
decreased intubation rates, decreased complication rates,
or decreased length of ICU stay. Once such a trial has
been performed, further studies can be done in patients
undergoing severe alcohol withdrawal to help precisely
define the indications, dosing schedule, and timing for
this promising therapy.
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